INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Results

24,511 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
15
TR
ten Bosch John RoderickSVP of Laboratory Operations
BLLNBillionToOne, Inc.
Open-market sale · 10b5-1 plan
SELL$160K
1,417 sh
Nov 2, 2026
Page 32 of 613
← PrevNext →
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC Form 4

Evidence

15
AO
Atay OguzhanDirector, Chairman and CEO
BLLNBillionToOne, Inc.
Open-market sale · 10b5-1 plan
SELL$159K
1,482 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

15
TR
ten Bosch John RoderickSVP of Laboratory Operations
BLLNBillionToOne, Inc.
Open-market sale · 10b5-1 plan
SELL$160K
1,417 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

15
TD
Tsao DavidDirector, Chief Technology Officer
BLLNBillionToOne, Inc.
Open-market sale · 10b5-1 plan
SELL$219K
1,992 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

15
AO
Atay OguzhanDirector, Chairman and CEO
BLLNBillionToOne, Inc.
Open-market sale · 10b5-1 plan
SELL$124K
1,117 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

15
LD
Ledingham DianneDirector
PEGAPEGASYSTEMS INC
Open-market sale · 10b5-1 plan
SELL$34K
1,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

14
MK
McCulloch KevinSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$153K
15.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

14
PS
Pieper StevenSee Remarks
XERSXeris Biopharma Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$51K
5,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

14
AO
Atay OguzhanDirector, Chairman and CEO
BLLNBillionToOne, Inc.
Open-market sale · 10b5-1 plan
SELL$302K
2,667 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

14
AO
Atay OguzhanDirector, Chairman and CEO
BLLNBillionToOne, Inc.
Open-market sale · 10b5-1 plan
SELL$302K
2,667 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

14
JT
Jampol ThadChief Product Officer
INTAIntapp, Inc.
Open-market sale · 10b5-1 plan
SELL$210K
5,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

14
MH
Murray Jason HulseDirector, Co-Founder, CEO & Chairman, 10% Owner
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$998K
21.4K sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

14
MH
Murray Jason HulseDirector, Co-Founder, CEO & Chairman, 10% Owner
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$301K
6,197 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC Form 4

Evidence

14
MH
Murray Jason HulseDirector, Co-Founder, CEO & Chairman, 10% Owner
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$612K
12.3K sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC Form 4

Evidence

14
MH
Murray Jason HulseDirector, Co-Founder, CEO & Chairman, 10% Owner
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$595K
11.6K sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC Form 4

Evidence

14
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$40K
600 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

14
HM
Hancock MarkDirector, 10% Owner
PACSPACS Group, Inc.
Open-market sale · 10b5-1 plan
SELL$605K
11.8K sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC Form 4

Evidence

13
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$50K
120 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
RA
Raabe Kyle AndrewPresident, Home Power Gen.
GNRCGENERAC HOLDINGS INC.
Open-market sale · 10b5-1 plan
SELL$81K
386 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

13
TS
Tang StanleyDirector
DASHDoorDash, Inc.
Open-market sale · 10b5-1 plan
SELL$846K
4,493 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$33K
80 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$49K
120 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
FJ
Fesko JohnPRESIDENT, CHIEF BUS. OFFICER
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$2,717
7 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
SR
Swanson Luke RoyCHIEF TECHNOLOGY OFFICER
IBTAIbotta, Inc.
Open-market sale · 10b5-1 plan
SELL$31K
470 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

13
RD
Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$2,717
7 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
CL
Chapman Steven LeonardDirector, CEO AND PRESIDENT
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$8,146
21 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
BJ
Bidzos D JamesDirector, Exec. Chairman, Pres, & CEO
VRSNVERISIGN INC/CA
Open-market sale · 10b5-1 plan
SELL$119K
380 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

13
BJ
Bidzos D JamesDirector, Exec. Chairman, Pres, & CEO
VRSNVERISIGN INC/CA
Open-market sale · 10b5-1 plan
SELL$201K
640 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

13
BJ
Bidzos D JamesDirector, Exec. Chairman, Pres, & CEO
VRSNVERISIGN INC/CA
Open-market sale · 10b5-1 plan
SELL$202K
640 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

13
CV
Coloma Jason VDirector, Chief Executive Officer
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$68K
2,257 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
BJ
Bidzos D JamesDirector, Exec. Chairman, Pres, & CEO
VRSNVERISIGN INC/CA
Open-market sale · 10b5-1 plan
SELL$63K
200 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

13
KJ
Kasbar Michael JDirector, Executive Chairman
WKCWORLD KINECT CORP
Open-market sale · 10b5-1 plan
SELL$72K
1,938 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$3,494
9 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
MS
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$49K
120 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
BB
Brophy Michael BurkesCHIEF FINANCIAL OFFICER
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$3,104
8 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
GB
Gordon William BDirector
DUOLDuolingo, Inc.
Open-market sale · 10b5-1 plan
SELL$182K
1,326 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
GB
Gordon William BDirector
DUOLDuolingo, Inc.
Open-market sale · 10b5-1 plan
SELL$190K
1,374 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
SJ
Sheena JonathanDirector, CO-FOUNDER
NTRANatera, Inc.
Open-market sale · 10b5-1 plan
SELL$1,165
3 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
SF
Sine Jared F.Chief Strategy & Legal Officer
GDDYGoDaddy Inc.
Open-market sale · 10b5-1 plan
SELL$118K
1,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

13
GB
Gordon William BDirector
DUOLDuolingo, Inc.
Open-market sale · 10b5-1 plan
SELL$240K
1,759 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence